NEXIEN BIOPHARMA, INC.
company.status.inactiveCIK 1625288fmd_17CQ1854VY5KDYE8X1GDYQ6QMKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2013 to Mar 31, 2025, 46 periods
Latest annual · FY2021
Millions- Operating income
- 10
- Net income
- (0)
Latest quarter · Q3 FY2025
Millions- Operating income
- (0)
- Net income
- (0)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
NEXIEN BIOPHARMA, INC. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Net income | -$239,113 | -$361,902 | 10-K 2024-10-22 · proof | |
| Cash from operating activities | -$64,364 | -$81,751 | 10-K 2024-10-22 · proof | |
| Total assets | $4,183 | $43,127 | -90.3% | 10-K 2024-10-22 · proof |
| Total liabilities | $365,432 | $295,134 | +23.8% | 10-K 2024-10-22 · proof |
| Cash and cash equivalents | $4,183 | $35,147 | -88.1% | 10-K 2024-10-22 · proof |
- What was NEXIEN BIOPHARMA, INC.'s net income in fiscal 2024?
- NEXIEN BIOPHARMA, INC. reported net income of -$239,113 for fiscal 2024 (the year ended Jun 30, 2024), against -$361,902 the year before. Source: the 10-K filed with the SEC on Oct 22, 2024. SEC
- What was NEXIEN BIOPHARMA, INC.'s cash from operating activities in fiscal 2024?
- NEXIEN BIOPHARMA, INC. reported cash from operating activities of -$64,364 for fiscal 2024 (the year ended Jun 30, 2024), against -$81,751 the year before. Source: the 10-K filed with the SEC on Oct 22, 2024. SEC
- What are NEXIEN BIOPHARMA, INC.'s total assets?
- As of Jun 30, 2024, NEXIEN BIOPHARMA, INC. reported total assets of $4,183, against $43,127 a year earlier (-90.3%). Source: the 10-K filed with the SEC on Oct 22, 2024. SEC
- What are NEXIEN BIOPHARMA, INC.'s total liabilities?
- As of Jun 30, 2024, NEXIEN BIOPHARMA, INC. reported total liabilities of $365,432, against $295,134 a year earlier (+23.8%). Source: the 10-K filed with the SEC on Oct 22, 2024. SEC
- What are NEXIEN BIOPHARMA, INC.'s cash and cash equivalents?
- As of Jun 30, 2024, NEXIEN BIOPHARMA, INC. reported cash and cash equivalents of $4,183, against $35,147 a year earlier (-88.1%). Source: the 10-K filed with the SEC on Oct 22, 2024. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1625288&period_type=annual&limit=5"Information only, not investment advice.